Eldepryl 5 mg Tablets
*Company:
Orion Pharma (Ireland) LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 31 July 2023
File name
Eldepryl 5mg tabl PIL 100523.pdf
Reasons for updating
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 31 July 2023
File name
Eldepryl 5mg tabl PIL 100523.pdf
Reasons for updating
- Change to section 5 - how to store or dispose
- Change to date of revision
Updated on 31 July 2023
File name
Eldepryl 5mg tabl SPC 100523.pdf
Reasons for updating
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 18 February 2021
File name
Eldepryl 5mg tabl PIL 120121.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Free text change information supplied by the pharmaceutical company
The following information has been added to the leaflet (warnings and precautions):
The use of Eldepryl together with buprenorphine can lead to serotonin syndrome, a potentially life-threatening condition.
Updated on 18 February 2021
File name
Eldepryl 5mg tabl SPC 150221.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.4: Information on concomitant buprenorphine added:
Concomitant administration of selegiline and buprenorphine may result in serotonin syndrome, a potentially life-threatening condition. If concomitant treatment with buprenorphine is clinically warranted, careful observation of the
patient is advised, particularly during treatment initiation and dose increases. Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms.
Section 4.5: Information on stopping Eldepry and starting a contra-indicated medication:
At least two weeks should elapse after stopping administration of Eldepryl before starting therapy with any contra-indicated medicinal product.
Updated on 26 November 2019
File name
Eldepryl 5mg tabl PIL 240315.pdf
Reasons for updating
- New PIL for new product
Updated on 26 November 2019
File name
Eldepryl 5mg tabl SPC 240315.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Orion Pharma (Ireland) Ltd
 Ltd.webp)
Address:
c/o Allphar Services Ltd, 4045 Kingswood Road, Citywest Business Park, Co Dublin D24V06KMedical Information E-mail:
ie.medicalinformation@orionpharma.comWebsite:
https://www.orionpharma.ieMedical Information Direct Line:
+353 1 468 8482Customer Care direct line:
+353 1 428 7777